Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.

No one should expect to be paying less for medicine anytime soon, experts say, though the drugmakers’ response to public pressure may help slow the rise in prices for some drugs.

The latest drugmaker move came Monday, when Johnson & Johnson, the world’s biggest maker of health care products, issued its first public report on price increases for its drugs.

The political and public anger over drug prices has been stirred by a few factors: Sky-high prices for new drugs, enormous increases for many existing drugs, and changes in insurance coverage that make patients pay a bigger portion of the drug bill.

Health-care alliance calls for action to lower prescription-drug costs Laurie McGinley

A broad coalition including health-care providers, insurers and seniors will propose major changes today designed to rein in prescription-drug costs, including a shorter exclusivity period for biotech medications and a requirement that manufacturers disclose more information about pricing.The Campaign…

A broad coalition including health-care providers, insurers and seniors will propose major changes today designed to rein in prescription-drug costs, including a shorter exclusivity period for biotech medications and a requirement that manufacturers disclose more information about pricing.The Campaign…

(Laurie McGinley)

The drug industry’s top two lobbying groups have been running advertising campaigns that reinforce a point the industry has long pushed: Medical breakthroughs that improve or save patients’ lives are very difficult — and expensive — and high prices are needed to fund research into new treatments.

But now individual companies are making their own cases to the public in hopes of showing that at least they aren’t as bad as some other guys.

On Monday, Johnson & Johnson reported that over the past five years, the list price, or retail price, of its drugs rose less than 10 percent each year on average, while the net price, the payment it receives after discounts and fees insurers and other middlemen get, rose 5 percent or less per year.

That’s far less than some of the eye-popping price increases that have been criticized over the past year, like the 547 percent jump over 9 years in the price of the EpiPen emergency allergy auto-injectors.

Trump had a good idea on drug costs. He ditched it after meeting with pharma execs. Joe Nocera

It wasn’t all that long ago — though it seems that way, admittedly, with the never-ending flood of Trumpian news — that I was prepared to acknowledge that President Donald Trump actually has a few good ideas. Or at least one.

It was Tuesday morning. The new president was about to go into a meeting…

It wasn’t all that long ago — though it seems that way, admittedly, with the never-ending flood of Trumpian news — that I was prepared to acknowledge that President Donald Trump actually has a few good ideas. Or at least one.

It was Tuesday morning. The new president was about to go into a meeting…

(Joe Nocera)

But J&J’s increase is still more than double the U.S. rate of inflation, which means its prices rose far faster than prices for other goods and services.

Johnson & Johnson’s disclosure is the latest in a string of similar moves.

Sanofi SA, maker of top-selling insulin Lantus, reported earlier this month that last year its list prices increased by 2.3 percent on average, but its average net price dipped 0.5 percent because insurers got discounts that averaged 50 percent. Merck & Co. in January reported its annual net price increase since 2010 has ranged from 3.4 percent to 6.2 percent, roughly half its list price increases, while its average discount to payers climbed to 41 percent in 2016.

Allergan CEO Brent Saunders kicked off the trend last fall when he announced the Botox maker had ended big list price hikes and would stick to single-digit increases. Novo Nordisk and AbbVie Inc. later followed suit.

Other companies, including GlaxoSmithKline and Takeda Pharmaceuticals, say they’ve been keeping annual list price increases below 10 percent, though they’re not making pledges. And Eli Lilly is reducing prices for most of its insulins up to 40 percent for people who pay the full price.

Trump calls drug pricing ‘astronomical’ and promises changes Anna Edney

President Donald Trump told drugmakers at a White House meeting Tuesday they were charging too much and promised to get better bargains for government health programs, in addition to finding ways to get new medicines to market faster.

“The pricing has been astronomical,” Trump said to chief executives…

President Donald Trump told drugmakers at a White House meeting Tuesday they were charging too much and promised to get better bargains for government health programs, in addition to finding ways to get new medicines to market faster.

“The pricing has been astronomical,” Trump said to chief executives…

(Anna Edney)

These moves might translate to smaller price increases, according to Edward Jones analyst Ashtyn Evans.

"I think in the near term, we are certainly going to see smaller price increases. We’ve already seen that this year," she says. "But it’s possible that if the headlines die down and the government doesn’t take action, that they could creep back up again."

Ed Schoonveld, a former pricing director at three drugmakers and now a managing partner at consultants ZS Associates, predicts "most companies will probably jump on board" because the industry wants to escape the pricing uproar.

Not everyone, though.

Pfizer Inc., the biggest U.S. drugmaker, says there’s no need for such pledges. Like the industry trade groups, it blames the furor on a handful of "irresponsible" companies that raised prices many times over for older products, the way Turing Pharmaceuticals, Valeant Pharmaceuticals International Inc. and EpiPen maker Mylan NV have done.

Schoonveld said no matter what pledges companies make, overall drug spending will continue to rise as costly new therapies emerge and the population ages.

And high prices will continue to shock the public: Earlier this month Marathon Pharmaceuticals LLC triggered a huge backlash by announcing it would charge $89,000 a year for its muscular dystrophy drug Emflaza, an old steroid that some patients had been importing from other countries for roughly $1,000 per year. Marathon has since delayed Emflaza’s launch while it talks with patients and advocacy groups about ensuring access to the drug.

Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan’s Ross School of Business, is not impressed with the pledges to keep annual list price increases below 10 percent, noting that those price hikes add up quickly.

"They’re doing everything but the obvious, simple thing — just lower the price," Gordon says.

Our editors found this article on this site using Google and regenerated it for our readers.